Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 1;42(2):141-149.
doi: 10.3343/alm.2022.42.2.141.

Clinical Practice Guidelines for Pre-Analytical Procedures of Plasma Epidermal Growth Factor Receptor Variant Testing

Saeam Shin  1 , Hye In Woo  2 , Jong-Won Kim  2 , Yoonjung Kim M D  1 , Kyung-A Lee  1
Affiliations
Review

Clinical Practice Guidelines for Pre-Analytical Procedures of Plasma Epidermal Growth Factor Receptor Variant Testing

Saeam Shin et al. Ann Lab Med. .

Abstract

Standardization of cell-free DNA (cfDNA) testing processes is necessary to obtain clinically reliable results. The pre-analytical phase of cfDNA testing greatly influences the results because of the low proportion and stability of circulating tumor DNA (ctDNA). In this review, we provide evidence-based clinical practice guidelines for pre-analytical phase procedures of plasma epidermal growth factor receptor gene (EGFR) variant testing. Specific recommendations for pre-analytical procedures were proposed based on evidence from the literature and our experimental data. Standardization of pre-analytical procedures can improve the analytical performance of cfDNA testing.

Keywords: Cell-free nucleic acid; Circulating tumor DNA; Clinical practice guidelines; Epidermal growth factor receptor; Pre-analytical phase.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflicts of interest relevant to this article are reported.

References

    1. Langer CJ. Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol. 2013;31:3303–6. doi: 10.1200/JCO.2013.49.8782. - DOI - PubMed
    1. Chae H, Sung PS, Choi H, Kwon A, Kang D, Kim Y, et al. Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma. Ann Lab Med. 2021;41:198–206. doi: 10.3343/alm.2021.41.2.198. - DOI - PMC - PubMed
    1. Ministry of Health and Welfare of South Korea, author. [Updated on Oct 2017];Notice of safety and efficacy of new medical device. https://www.mohw.go.kr/react/jb/sjb0406vw.jsp .
    1. Li X, Zhou C. Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer. Oncotarget. 2017;8:100801–18. doi: 10.18632/oncotarget.19007. - DOI - PMC - PubMed
    1. Passiglia F, Rizzo S, Di Maio M, Galvano A, Badalamenti G, Listì A, et al. The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. Sci Rep. 2018;8:13379. doi: 10.1038/s41598-018-30780-4. - DOI - PMC - PubMed